G Logan Douds1, Anne S Hellkamp2, DaiWai M Olson2, Gregg C Fonarow3, Eric E Smith4, Lee H Schwamm5, Kevin M Cockroft6. 1. Penn State Hershey Stroke Center, Penn State Hershey Medical Center, Hershey, Pennsylvania. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. Division of Cardiology, University of California, Los Angeles, Los Angeles, California. 4. Calgary Stroke Program, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 5. Stroke Service, Massachusetts General Hospital, Boston, Massachusetts. 6. Penn State Hershey Stroke Center, Penn State Hershey Medical Center, Hershey, Pennsylvania. Electronic address: kcockroft@psu.edu.
Abstract
BACKGROUND: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolus (PE), represents a serious complication in hospitalized ischemic stroke patients. This study examines the incidence of VTE and the patterns of VTE prophylaxis in acute ischemic stroke patients deemed appropriate for VTE prophylaxis (nonambulatory) in the Get With The Guidelines-Stroke (GWTG-S) study. METHODS: We analyzed data from 149,916 patients who were admitted with acute ischemic stroke and enrolled in GWTG-S from 1259 U.S. hospitals. Patient variables and site characteristics were analyzed in relation to reported administration of VTE prophylaxis. RESULTS: The overall rate of VTE prophylaxis in the analysis cohort was 93% (139,476/149,916). The median site prophylaxis rate was 95%, and prophylaxis rates ranged from 17% (1 site) to 100% (101 sites). Factors associated with increased likelihood of VTE prophylaxis in the multivariable model included history of atrial fibrillation/flutter, receipt of intravenous or intra-arterial tissue plasminogen activator, and admission to an academic hospital. Increasing age, black race, and a history of peripheral vascular disease, diabetes, or stroke were associated with lower likelihood of prophylaxis. Patients receiving care in the Midwest were less likely to receive prophylaxis compared to other regions. CONCLUSIONS: Despite a high overall rate of VTE prophylaxis, VTE was found to occur in approximately 3% of GWTG-S patients. Reported rates of VTE prophylaxis differed among hospitals by region and hospital type, and among patients by age, race, and medical comorbidities.
BACKGROUND:Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolus (PE), represents a serious complication in hospitalized ischemic strokepatients. This study examines the incidence of VTE and the patterns of VTE prophylaxis in acute ischemic strokepatients deemed appropriate for VTE prophylaxis (nonambulatory) in the Get With The Guidelines-Stroke (GWTG-S) study. METHODS: We analyzed data from 149,916 patients who were admitted with acute ischemic stroke and enrolled in GWTG-S from 1259 U.S. hospitals. Patient variables and site characteristics were analyzed in relation to reported administration of VTE prophylaxis. RESULTS: The overall rate of VTE prophylaxis in the analysis cohort was 93% (139,476/149,916). The median site prophylaxis rate was 95%, and prophylaxis rates ranged from 17% (1 site) to 100% (101 sites). Factors associated with increased likelihood of VTE prophylaxis in the multivariable model included history of atrial fibrillation/flutter, receipt of intravenous or intra-arterial tissue plasminogen activator, and admission to an academic hospital. Increasing age, black race, and a history of peripheral vascular disease, diabetes, or stroke were associated with lower likelihood of prophylaxis. Patients receiving care in the Midwest were less likely to receive prophylaxis compared to other regions. CONCLUSIONS: Despite a high overall rate of VTE prophylaxis, VTE was found to occur in approximately 3% of GWTG-Spatients. Reported rates of VTE prophylaxis differed among hospitals by region and hospital type, and among patients by age, race, and medical comorbidities.
Authors: Michel T Torbey; Julian Bösel; Denise H Rhoney; Fred Rincon; Dimitre Staykov; Arun P Amar; Panayiotis N Varelas; Eric Jüttler; DaiWai Olson; Hagen B Huttner; Klaus Zweckberger; Kevin N Sheth; Christian Dohmen; Ansgar M Brambrink; Stephan A Mayer; Osama O Zaidat; Werner Hacke; Stefan Schwab Journal: Neurocrit Care Date: 2015-02 Impact factor: 3.210
Authors: Nohra Chalouhi; Badih Daou; Fred Rincon; Maria Montano; Anthony Kent; Kaitlyn Barkley; Robert M Starke; Stavropoula Tjoumakaris; David Hasan; Richard Dalyai; Robert Rosenwasser; Pascal Jabbour Journal: Neurocrit Care Date: 2016-08 Impact factor: 3.210
Authors: Jason-Flor V Sisante; Michael G Abraham; Milind A Phadnis; Sandra A Billinger; Manoj K Mittal Journal: J Stroke Cerebrovasc Dis Date: 2016-07-14 Impact factor: 2.136
Authors: Muhammad T Khan; Asad Ikram; Omar Saeed; Taha Afridi; Cathy A Sila; Matthew S Smith; Khadija Irshad; Ashfaq Shuaib Journal: Cureus Date: 2017-12-23